61 drugs found substandard in 19 pharmaceutical industries in Himachal

Nalagarh:  As many as 24 medicines, syrups and injections manufactured in 19 pharmaceutical industries in Himachal Pradesh have been found to be substandard in a probe conducted by the Central Drugs Standard Control Organisation (CDSCO). Medicines that have not met the quality scale.

According to the information, they include medicines used in the treatment of pain including fungal infections, cancer, type 2 diabetes, severe bacterial infections, cardiac arrest, antibiotics, respiratory diseases, anti-inflammatory drugs, angina, Alzheimer’s, antiparasitic, stomach ulcers, fever.

These medicines have been manufactured in pharmaceutical industries located in Baddi, Barotiwala, Waknaghat, Paonta Sahib. Five samples from the Baddi-based Effi Pharma industry have failed. The state drug control authority has already taken action against this industry and banned the production of the drug.

In the drug alert issued by the CDSCO for the month of October, 37 drugs manufactured in New Delhi, Jammu, Rajasthan, Bihar Uttarakhand, Bengaluru, Kolkata, Uttar Pradesh, Punjab, Rajasthan, Gujarat, Maharashtra, Chennai have also been found to be substandard.

The State Drug Controller has issued notices to all the pharmaceutical companies involved in the drug alert and has issued instructions to immediately recall the entire batch of the concerned drug from the market. Along with this, assistant drug controllers have been instructed to jointly inspect all pharmaceutical industries and submit a detailed investigation report.

Meanwhile, State Drug Controller Navneet Marwah said that show-cause notices have been issued to all the concerned pharmaceutical companies involved in the drug alert for the month of October issued by the CDSCO and instructions have been given to recall the entire stock of the concerned batch. Apart from this, strict action will be taken against those industries whose samples are failing repeatedly.

Related Posts

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

New Delhi: AstraZeneca’s India-arm has partnered with National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, to build clinical research capabilities at 25 emerging geographies in a bid to extend…

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

Following a bumpy regulatory road that involved a refusal-to-file, ImmunityBio has won FDA approval to expand Anktiva into papillary-only non-muscle-invasive bladder cancer (NMIBC). Wednesday’s approval comes nearly three months ahead…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

‘Bone Bonding’ between Mothers and Children, thanks to Meticulous Bone Grafting

‘Bone Bonding’ between Mothers and Children, thanks to Meticulous Bone Grafting

Governments have moved for Price Transparency in Hospitals to help patients cope with bills

Governments have moved for Price Transparency in Hospitals to help patients cope with bills

The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction